Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh
The Davol/C.R. Bard hernia mesh litigation consolidates claims that polypropylene mesh implants used in hernia repair degrade, migrate, or provoke chronic inflammatory reactions, producing pain, adhesions, bowel injury, and, in many cases, a second surgery to remove or revise the mesh. This is a distinct MDL from other hernia mesh litigation proceeding against different manufacturers, and its structure — one manufacturer's product line, consolidated before a single transferee judge — is what allows a docket of this scale to develop consistent, transferable case-management tools across tens of thousands of claims.
In a docket this large and this mature, duration and resolution risk are driven less by an unresolved general-causation dispute — mesh-related complications and their mechanisms are well documented in the scientific and clinical literature by this stage — and more by how the transferee court sequences case-specific development across a claim population with widely varying injury severity, from chronic pain without mesh removal to multiple revision surgeries. Bellwether-style trial and discovery mechanisms in a docket this size typically exist to generate representative outcome information across that severity spectrum, informing how the broader claim population ultimately resolves, whether through individual trials, negotiated settlement mechanisms, or a combination of both.
Remand risk grows for any claims that do not resolve through a negotiated mechanism once the transferee court's coordinated pretrial work is complete, returning those cases to their originating districts for trial.
This is precisely the kind of structural complexity — claim-severity tiering, sequencing mechanics, procedural posture — that Criterica Intelligence's regulated outcomes intelligence is built to make legible, without collapsing it into a single predicted win rate or dollar figure. Criterica Intelligence applies this same structural lens across every active MDL, from dockets this large down to the smallest, newly centralized litigation, and updates that read as procedural posture continues to shift.
It consolidates claims that polypropylene hernia mesh implants degrade, migrate, or trigger chronic inflammatory reactions, causing pain, adhesions, bowel injury, and often a second surgery to remove or revise the mesh. Claims are centralized before Judge Edmund A. Sargus in the Southern District of Ohio.
Polypropylene hernia mesh has been widely implanted for years across a large patient population, and this MDL consolidates one manufacturer's product line specifically, distinct from other hernia mesh litigation against different defendants.
How the transferee court sequences bellwether-style case development and negotiated resolution mechanisms across a large, injury-tiered claim population, since courts cannot individually try tens of thousands of claims one at a time.
Cases not resolved through negotiated mechanisms are generally remanded to their originating districts for individual trial once coordinated pretrial proceedings in the MDL are complete, following standard federal MDL procedure.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.